Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.

<h4>Introduction</h4>Current treatments for overactive bladder (OAB) are often discontinued due to side effects or lack of efficacy. The goal of this study was to determine if combining a phosphodiesterase type 4 inhibitor (PDE4i); with a type 5 inhibitor (PDE5i); would have a beneficial...

Full description

Bibliographic Details
Main Authors: Brian M Balog, Abhilasha Tangada, Pooja Sheth, Qi-Xiang Song, Bruna M Couri, Leah L Porras, Gary G Deng, Margot S Damaser
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0220788

Internet

https://doi.org/10.1371/journal.pone.0220788

Similar Items